J Thorac Oncol 2006, 1:260–267.PubMed 23. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S: Evaluation of epidermal growth factor receptor EX 527 mutation status in serum DNA as a predictor

NVP-BGJ398 of response to gefitinib (IRESSA). Br J Cancer 2007, 97:778–784.PubMedCrossRef 24. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366–377.PubMedCrossRef 25. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, Jänne PA: Noninvasive detection of EGFR T790M in gefitinib

or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630–2636.PubMedCrossRef 26. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR: EGFR mutations detected Selleck ACY-1215 in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009, 4:1466–1472.PubMedCrossRef 27. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, Caicun Z: Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:1341–1347.PubMedCrossRef 28. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, all Liu HN, Wang YY, Wang J: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653–2659.PubMedCrossRef 29. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J: Detection of epidermal growth factor receptor mutations in plasma

by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009, 125:2393–2399.PubMedCrossRef 30. Jiang B, Liu F, Yang L, Zhang W, Yuan H, Wang J, Huang G: Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011, 39:1392–1401.PubMedCrossRef 31. Brevet M, Johnson ML, Azzoli CG, Ladanyi M: Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011, 73:96–102.PubMedCrossRef 32.